Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Pathology Oncology Research : POR
Tímea BalatoniGabriella Liszkay

Abstract

Ipilimumab was the first immunotherapy approved for metastatic melanoma in decades and is currently registered as a second-line treatment. However, new immunotherapies, in combination with ipilimumab, offer even better clinical outcomes for patients compared with single-agent treatments, at the expense of improved toxicity. The aim of this study was to evaluate the feasibility of ipilimumab outside the clinical trials and to identify survival predictors for treatment benefit. Data were collected on 47 advanced melanoma patients treated with ipilimumab between 2010 and 2015 at a single center. Association of clinical characteristics (including primary tumor characteristics), serum lactate dehydrogenase (LDH), erythrocyte sedimentation rate, absolute eosinophil, lymphocyte, and neutrophil count, neutrophil/lymphocyte and eosinophil/lymphocyte ratio with toxicity and clinical outcome were assessed using univariate and multivariate analysis. Median progression-free survival at a median follow-up of 10 months was 2.7 months and median overall survival was 9.8 months. Objective response was observed in 17% of patients and the disease control rate at week 24 was 40%. The 1- and 2-year survival rates documented were 40 and 28%, respect...Continue Reading

References

Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Sep 3, 2004·The New England Journal of Medicine·Hensin TsaoArthur J Sober
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter AttiaSteven A Rosenberg
Jun 30, 2006·Expert Opinion on Biological Therapy·Christian A PetrulioHoward L Kaufman
Mar 21, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ljubov SimsonChristopher R Parish
Nov 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephanie G DowneySteven A Rosenberg
May 19, 2009·Expert Review of Anticancer Therapy·Sanjiv S Agarwala
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Oct 27, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Julie A EllerhorstElizabeth A Grimm
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
May 7, 2011·Molecular Pharmaceutics·Elizabeth A Vasievich, Leaf Huang
May 28, 2011·Pigment Cell & Melanoma Research·Bianca DevittGrant McArthur
Mar 30, 2012·The Lancet Oncology·Kim MargolinF Stephen Hodi
Apr 23, 2013·Critical Reviews in Oncology/hematology·Graeme J K GuthrieStephen J Clarke
May 31, 2014·Journal of the National Cancer Institute·Arnoud J TempletonEitan Amir
Jul 22, 2014·Melanoma Research·Alfonso BerrocalUNKNOWN Spanish Melanoma Group
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Mar 5, 2015·Cancer Immunology Research·Douglas B JohnsonJeffrey A Sosman
Mar 31, 2015·Pigment Cell & Melanoma Research·Andrea Ladányi
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Aug 1, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S ValpioneV Chiarion-Sileni
Aug 21, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christoffer GebhardtViktor Umansky
Nov 26, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stefan DiemJames Larkin
Jan 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander MartensBenjamin Weide

❮ Previous
Next ❯

Citations

Dec 24, 2018·Expert Opinion on Investigational Drugs·Bartosz SzostakAndrzej Pawlik
Dec 6, 2019·Current Medicinal Chemistry·Martina StrudelPaolo A Ascierto
Mar 30, 2019·Journal for Immunotherapy of Cancer·Christine Ménétrier-CauxChristophe Caux

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

Recist
Statistica

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.